Submitted: 10 January 2012
Accepted: 10 January 2012
Published: 10 January 2012
Abstract Views: 876
PDF: 1209
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.


Chronic Myeloid Leukemia (CML) is a myeloproliferative pluripotent stem cell disorder characterized by the presence of a cytogenetic hallmark, the Philadelphia (Ph) chromosome, and accounts for 15% of adult leukemias. The disease progresses from a chronic phase through an accelerated phase to a blast phase and its natural course accounts for a median 4 years survival1. The Ph chromosome is derived by a reciprocal translocation termed t(9;22) in which the c-abl oncogene has moved from chromosome 9 into the breakpoint cluster region (bcr), within the bcr gene on chromosome 22, resulting in a chimeric bcr-abl fusion gene that encodes a 210 KD protein (p210) with constitutive tyrosine kinase activity. Two major alternative chimeric p210 can result from this fusion gene: p210-b2a2 where the junction occurs between bcr exon 2 (b2) and abl exon 2 (a2) and p210-b3a2 where the the junction occurs between bcr exon 3 (b3) and abl exon 2 (a2. About 40% of CML patients harbor the p210-b2a2 and about 60% of them show the p210-b3a2.



PlumX Metrics


Download data is not yet available.


How to Cite

Bocchia, M., Ippoliti, M., Defina, M., Gozzetti, A., Chitarrelli, I., & Lauria, F. (2012). BCR-ABL DERIVED PEPTIDE VACCINES FOR CHRONIC MYELOID LEUKAEMIA. Journal of the Siena Academy of Sciences, 1(1), 11–14. https://doi.org/10.4081/jsas.2009.328